Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Queensland Health
Citi
UBS
Boehringer Ingelheim
Moodys
Mallinckrodt
Fuji

Generated: October 15, 2018

DrugPatentWatch Database Preview

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard

What are the generic sources for hydrochlorothiazide; labetalol hydrochloride and what is the scope of hydrochlorothiazide; labetalol hydrochloride patent protection?

Hydrochlorothiazide; labetalol hydrochloride is the generic ingredient in two branded drugs marketed by Schering and Glaxosmithkline, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for hydrochlorothiazide; labetalol hydrochloride.

Summary for HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE
US Patents:0
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: 32
Clinical Trials: 1
DailyMed Link:HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE at DailyMed

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-003 Apr 6, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-004 Apr 6, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-003 Apr 10, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-003 Apr 6, 1987 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-004 Apr 10, 1987 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRANDATE HCT hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019174-003 Apr 10, 1987 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Queensland Health
Citi
UBS
Boehringer Ingelheim
Moodys
Mallinckrodt
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.